Our technology platform produces synthetic peptides, that are based on naturally occurring proteins - ImotopesTM - the next generation of targeted immunotherapeutics using the patient’s own immune system to break the abnormal immune responses thereby recalibrating the immune system.
The ImotopeTM platform has the potential to address a wide range of immunologic diseases. Our robust pipeline consists of two clinical and three pre-clinical programs, initially targeting Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Neuromyelitis Optica and Celiac Disease.
To drive the development and commercialization of our wide range of clinical and pre-clinical programs we are focused on advancing assets both in-house and through strategic partnerships.
